Enlivex Therapeutics shares fall 1.94% premarket after announcing new patent for osteoarthritis treatment.

Enlivex Therapeutics Ltd. declined 1.94% in premarket trading, following the announcement of the issuance of a new Israeli patent for the treatment of osteoarthritis. The patent, numbered 290470, titled 'THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS', provides Enlivex with added intellectual property protection in Israel through at least 2040. The company recently reported positive three-month topline data from the Phase IIa stage of ENX-CL-05-001, a clinical trial evaluating Allocetra™ in patients with moderate-to-severe knee osteoarthritis.